Neuro-Biotech Corp.: Conditions of Unsolicited Offer

BASEL, Switzerland, Feb. 16 /PRNewswire/ - Neuro-Biotech Corp. (PINKSHEET: MRES) (OTCQB: MRES) is pleased to provide its shareholders additional details about the unsolicited offer. The conditions to be met are as follows:

1. AURIC Pharma Science will provide financial statements proving its ability to complete the purchase.
2. AURIC Pharma Science will provide detailed distribution network of its products and services.
3. Neuro-Biotech Corp. will provide patent information on all its exclusive products and services.
4. Neuro-Biotech Corp. will provide all previous and effected purchase orders, as well as future pending orders.

Both companies will also be signing a Non-Disclosure Agreement for certain areas of their due diligence but Neuro-Biotech Corp. intends on disclosing all possible information to its shareholders along the process.

For more information on Neuro-Biotech Corp or to contact a company representative, please visit: www.neuro-biotechcorp.com

FORWARD LOOKING STATEMENTS

This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

SOURCE Neuro-Biotech Corp.